Studienleiter Dr. med. Jan Moritz Middeke
EudraCT-Nr. 2023-509055-14-00
Studientyp Offen, Phase II
Indikation Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation
ClinicalTrial NCT06717958